Sign in
SPRY Stock Price, Chart, Stats & News
ARS Pharmaceuticals, Inc.
Save
1.02B
Market cap
–
Current P/E
–
Forward P/E
SPRY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 75.77% |
Operating margin | -212.92% |
Pretax margin | -203.35% |
Net margin | -203.25% |
Effective tax rate | 0.05% |
ROA | -52.28% |
ROE | -100.29% |
D/E | 0.85x |
Interest coverage ratio | – |
SPRY valuation
P/E | – |
P/S | 9.51x |
P/B | 6.96x |
P/CF | -4.66x |
P/FCF | -4.68x |
P/OCF | -4.66x |
PEG | 0.04x |
EV multiple | -4.35x |
About
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray.
Similar securities
Based on sector and market capitalization
Report issue